Form 4: ClearPoint Neuro Director Exercises Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., converted 21,093 restricted stock units into common stock on May 16, 2025.

Summary

  • On May 16, 2025, Pascal E. R. Girin, a director of ClearPoint Neuro, Inc. (CLPT), converted 21,093 restricted stock units into shares of common stock.
  • The restricted stock units vested on the earlier of the first anniversary of the grant date or the day immediately preceding the company's 2025 annual meeting of stockholders.
  • Following the transaction, Girin directly owns 96,111 shares of ClearPoint Neuro common stock.

Sentiment

Score: 5

Explanation: This is a routine insider transaction, neither particularly positive nor negative. It reflects the standard vesting schedule of previously granted equity.

Industry Context

This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

  • The transaction increases the number of outstanding shares, which could have a minor dilutive effect on existing shareholders.

Key Dates

DateDescription
May 16, 2024Reporting person was granted 21,093 restricted stock units.
May 16, 2025Restricted stock units vested and were converted into common stock.
May 19, 2025Date of Form 4 filing.

Keywords

ClearPoint Neuro, CLPT, Form 4, Director, Stock Units, Girin, Insider Transaction, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.